AASLD/EASL HBV Treatment Endpoints Workshop

Publié le 29/08/2016

September 08-09, 2016

Alexandria, VA, USA

AASLD and EASL possess the expertise in chronic hepatitis B and D to bridge the current knowledge gaps that regulatory and pharmaceutical industry has identified as important issues hampering development of novel therapeutic agents for chronic hepatitis B and D.

This workshop will bring together the academic, regulatory and pharmaceutical communities to discuss therapeutic endpoints, trial designs and appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D.

http://www.aasld.org/events-professional-development/aasldeasl-hbv-treatment-endpoints-workshop?&utm_source=homepage&utm_medium=HBVEndpoints&utm_campaign=rotator

poster aasld-2016-eposter-radreau-et-al

À lire dans 'Événements'

• ENYO Pharma annonce la finalisation de son financement de série C avec Vesalius Biocapital et la poursuite de son étude clinique de phase 2 ALPESTRIA-1
• BIO International Convention
• Alport Connect 2025, la rencontre annuelle américaine avec les patients atteints du syndrome d’Alport
• 7ème CKD Drug Development Summit
• J.P. Morgan week et WuXi Global Forum 2025 à San Francisco